Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 355

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 355
---
 “cashless basis,” as described in the warrant agreement.

The Private Placement Warrants
are identical to the Public Warrants underlying the Units sold in the IPO, except that the Private Placement Warrants and the common stock
issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable, or salable until after the completion
of a business combination, subject to certain limited exceptions. The Private Placement Warrants will be redeemable by the Company and
exercisable by such holders on the same basis as the Public Warrants.

The exercise price and number
of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a
stock dividend, extraordinary dividend or recapitalization, reorganization, merger, or consolidation. However, the warrants will not be
adjusted for issuances of common stock at a price below their respective exercise prices, other than as set forth below. Additionally,
in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a business combination
within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any
of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the
Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if the Company
issues additional common stock or equity-linked securities for capital raising purposes in connection with the closing of a business combination
at an issue price or effective issue price of less than $ per share of common stock (with such issue price or effective issue price
to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Initial Stockholders
or their affiliates, without taking into account any Founder Shares held by them prior to such issuance) (the “Newly Issued Price”),
and (y) the aggregate gross proceeds from such issuances represent more than % of the total equity proceeds, and interest thereon,
available for the funding of a business combination on the date of the consummation of a business combination (net of redemptions), and
(z) the volume weighted-average trading price of the Company’s common stock during the 20-trading-day period starting
on the trading day prior to the day on which the Company consummates a business combination (such price, the “Market Value”)
is below $ per share